Full Text:   <1400>

CLC number: R392.11

On-line Access: 

Received: 2004-12-29

Revision Accepted: 2005-04-09

Crosschecked: 0000-00-00

Cited: 1

Clicked: 3532

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2005 Vol.6 No.9 P.873~876

10.1631/jzus.2005.B0873


Immunomodulatory function of orally administered thymosin α1


Author(s):  CHEN Xiang-ming, JIANG Han-liang, ZHOU Lin-fu, PAN Xiao-ping, HU Zhong-rong, LIU Rong-hua, CHEN Xiao-ming, CHEN Zhi

Affiliation(s):  Department of Anesthesiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   chenzhi@zju.edu.cn

Key Words:  Thymosin &alpha, 1, Yeast expression system, Biological activity, Orally administered


CHEN Xiang-ming, JIANG Han-liang, ZHOU Lin-fu, PAN Xiao-ping, HU Zhong-rong, LIU Rong-hua, CHEN Xiao-ming, CHEN Zhi. Immunomodulatory function of orally administered thymosin α1[J]. Journal of Zhejiang University Science B, 2005, 6(9): 873~876.

@article{title="Immunomodulatory function of orally administered thymosin α1",
author="CHEN Xiang-ming, JIANG Han-liang, ZHOU Lin-fu, PAN Xiao-ping, HU Zhong-rong, LIU Rong-hua, CHEN Xiao-ming, CHEN Zhi",
journal="Journal of Zhejiang University Science B",
volume="6",
number="9",
pages="873~876",
year="2005",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2005.B0873"
}

%0 Journal Article
%T Immunomodulatory function of orally administered thymosin α1
%A CHEN Xiang-ming
%A JIANG Han-liang
%A ZHOU Lin-fu
%A PAN Xiao-ping
%A HU Zhong-rong
%A LIU Rong-hua
%A CHEN Xiao-ming
%A CHEN Zhi
%J Journal of Zhejiang University SCIENCE B
%V 6
%N 9
%P 873~876
%@ 1673-1581
%D 2005
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2005.B0873

TY - JOUR
T1 - Immunomodulatory function of orally administered thymosin α1
A1 - CHEN Xiang-ming
A1 - JIANG Han-liang
A1 - ZHOU Lin-fu
A1 - PAN Xiao-ping
A1 - HU Zhong-rong
A1 - LIU Rong-hua
A1 - CHEN Xiao-ming
A1 - CHEN Zhi
J0 - Journal of Zhejiang University Science B
VL - 6
IS - 9
SP - 873
EP - 876
%@ 1673-1581
Y1 - 2005
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2005.B0873


Abstract: 
Objective: To investigate the immunological function of a yeast expression system for thymosin &alpha;1 (Tα1). Methods: A constructed Tα1 yeast expression system was used to investigate the immunological function of orally administered1. Dried yeast containing three different concentration of Tα1 was fed to normal Balb/c mice and other Balb/c mice whose immunities were inhibited in advance by cyclophosphamide. Synthesized Tα1 peptide was used as positive control and dried yeast with empty plasmid was used as negative control. CD4+ and CD8+ levels were detected by flow cytometry assay. TNF-α, IFN-γ, IL-2, IL-6 and IL-10 levels were detected by liquid chip. Results: In normal Balb/c mice or immune inhibition Balb/c mice, CD8+ levels were significantly increased. Especially in immune inhibition Balb/c mice, CD8+ levels in synthesized Tα1 group (18.77%±4.72%), small dose group (13.48%±6.17%) and large dose group (22.74%±1.09%) were significantly higher than that in empty yeast control group (7.49%±2.14%). Conclusion: orally administered1 has its certain immunomodulatory function.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Andreone, P., Cursaro, C., Gramenzi, A., Margotti, M., Ferri, E., Talarico, S., Biselli, M., Felline, F., Tuthill, C., Martins, E., Gasbarrini, G., Bernardi, M., 2001. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J. Viral. Hepat., 8(3):194-201.

[2] Garaci, E., Pica, F., Rasi, G., Favalli, C., 2000. Thymosin alpha 1 in the treatment of cancer: From basic research to clinical application. Int. J. Immunopharmacol., 22(12):1067-1076.

[3] Kullavanuaya, P., Treeprasertsuk, S., Thong-Ngam, D., Chaermthai, K., Gonlachanvit, S., Suwanagool, P., 2001. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J. Med. Assoc. Thai, 84(Suppl 1):S462-468.

[4] Saruc, M., Ozden, N., Turkel, N., Ayhan, S., Hock, L.M., Tuzcuoglu, I., Yuceyar, H., 2003. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J. Pharm. Sci., 92(7):1386-1395.

[5] Zavaglia, C., Airoldi, A., Pinzello, G., 2000. Antiviral therapy of HBV- and HCV-induced liver cirrhosis. J. Clin. Gastroenterol., 30(3):234-241.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE